FDA Warning Letters Decline, But Agency Says Enforcement Is Still Strong
Executive Summary
A report issued by a leading House Democrat shows that the number of warning letters issued by FDA dropped more than 50% over the last five years, but FDA staffers say the figures don't necessarily mean the agency has grown lax in its enforcement
You may also be interested in...
FDA Flu Vaccine Inspections Need More Compressed Timeframe – Rep. Davis
FDA's procedures for inspecting flu vaccine manufacturing facilities may need revision in light of the current supply shortage, House Government Reform Committee Chairman Tom Davis (R-Va.) suggested during a Nov. 17 hearing
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials